Skip to main content
Fig. 5 | Cancer Nanotechnology

Fig. 5

From: Development of glycan-targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment

Fig. 5

Biodistribution of 99mTc-non-targeted and 99mTc-sTn-targeted NPs in MKN45-ST6GalNAc-I tumor-bearing mice. A 99mTc-non-targeted or 99mTc-sTn-targeted NPs (3.7 MBq) were injected intravenously in MKN45-ST6GalNAc-I tumor-bearing Balb/c nude mice. One-hour post-injection, mice were euthanized, organs of interest were collected, weighted and radioactivity in each organ was measured. Data are presented as the mean (% ID/g of tissue) ± SD of n = 5. B Tumor-to-muscle ratio uptake of 99mTc-non-targeted and 99mTc-sTn-targeted NPs. Data were analyzed by one unpaired t-test (multiple t tests), *p < 0.05 and **p < 0.01

Back to article page